


Licogliflozin

05/20

ALTERNATE NAMES: LIK066; (2S,3R,4R,5S,6R)-2-[3-(2,3-dihydro-1,4-benzodioxin-6-ylmethyl)-4-ethylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol; (2S,3R,4R,5S,6R)-2-[3-(2,3-dihydro-benzo[1,4]dioxin-6-ylmethyl)-4-ethyl-phenyl]-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol

CATALOG #: B3028-1 1 mg
B3028-5 5 mg

STRUCTURE:



MOLECULAR FORMULA: C₂₃H₂₈O₇

MOLECULAR WEIGHT: 416.46

CAS NUMBER: 1291094-73-9

APPEARANCE: Solid

PURITY: ≥98%

SOLUBILITY: Soluble in DMSO

DESCRIPTION: Licogliflozin is a dual inhibitor of Sodium/glucose cotransporters SGLT1 and SGLT2 with a higher selectivity for SGLT2 (*in vitro* IC₅₀ values of 20.6 and 0.58 nM, respectively). It causes a reduction in body weight from baseline versus placebo after 24 weeks (50 mg twice daily). However, the percent decreases were numerically small (<5%). Higher doses of licogliflozin also reduce waist circumference, fasting plasma glucose, hemoglobin A1c (HbA1c), systolic blood pressure and triglycerides. It increases HDL cholesterol and 24-hour urinary glucose excretion.

STORAGE TEMPERATURE: -20°C

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCES: Licogliflozin, a Novel SGLT1 and 2 Inhibitor: Body Weight Effects in a Randomized Trial in Adults with Overweight or Obesity. Bays, H.E., Kozlovski, P., Shao, Q., et al. Obesity (Silver Spring). 28(5):870-881 (2020)

RELATED PRODUCTS:

Atorvastatin (Cat. No. 2278)
 Ipragliflozin (Cat. No. B1926)
 Mevastatin (Cat. No. 1694)
 Pitavastatin Calcium (Cat. No. B2090)
 Simvastatin (Cat. No. 1693)

DISCLAIMER: **FOR RESEARCH USE ONLY! Not to be used on humans.**